We are live on ! Find out more
JJ

Johnson & Johnson Portfolio holdings

AUM $799M
1-Year Est. Return 253.51%
This Fund
S&P 500
This Quarter Est. Return
+12.46%
1 Year Est. Return
+253.51%
3 Year Est. Return
+280.64%
5 Year Est. Return
+320.83%
10 Year Est. Return
–
AUM
$4.39B
AUM Growth
+$4.11B
Cap. Flow
+$3.71B
Cap. Flow %
84.63%
Top 10 Hldgs %
99.01%
Holding
26
New
2
Increased
2
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
KVUE icon
Kenvue
KVUE
+$3.65B
2
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$31.5M
3
NBTX
Nanobiotix
NBTX
+$29.6M
4
NMRA icon
Neumora Therapeutics
NMRA
+$11.5M

Top Sells

Rank Stock Value
1
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$6.67M
2
HLTH
Cue Health Inc. Common Stock
HLTH
+$2.45M
3
ALDX icon
Aldeyra Therapeutics
ALDX
+$294K
4
ACET icon
Adicet Bio
ACET
+$55K
5
GYRE icon
Gyre Therapeutics
GYRE
+$32.3K

Sector Composition

Rank Sector Weight
1 Consumer Staples 89.5%
2 Healthcare 10.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PNT
26
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
– –
-1,000,000
Closed -$6.67M
1
2

Similar funds

HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $797M AUM 4.79% 1-Year Est. Return
AGA
Arkos Global Advisors Houston, Texas $797M AUM 15.28% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
UM
Ulysses Management New York $802M AUM 5.35% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
AI
Aperture Investors New York $791M AUM 54.66% 1-Year Est. Return

Johnson & Johnson's Q4 2023 Portfolio in Review

As of Q4 2023, Johnson & Johnson held 26 positions worth $4.39B, up 1,516% from $271M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Johnson & Johnson deployed $3.71B of net new capital in Q4 2023, opening 2 new positions and adding to 2 existing holdings. Its largest new stake was Kenvue: 182,329,550 shares worth $3.93B.

By sector, the portfolio is most concentrated in Consumer Staples at 89% of assets, followed by Healthcare.

On the sell side, the largest reduction was Aldeyra Therapeutics, an estimated $294K trimmed.

  • Johnson & Johnson's largest Q4 2023 buy was Kenvue: 182,329,550 shares worth $3.93B.
  • Johnson & Johnson added most to Nanobiotix in Q4 2023, an estimated $29.6M increase.
  • Johnson & Johnson's biggest Q4 2023 reduction was Aldeyra Therapeutics, cutting an estimated $294K.
  • Johnson & Johnson fully exited POINT Biopharma Global Inc. Common Stock in Q4 2023, selling an estimated $6.67M.
  • Johnson & Johnson's ten largest holdings make up 99% of its $4.39B portfolio in Q4 2023.
  • Johnson & Johnson opened 2 new positions and closed 3 in Q4 2023.
  • Johnson & Johnson's portfolio value rose 1,516% quarter-over-quarter to $4.39B.

Based on Johnson & Johnson's 13F filing for Q4 2023, filed 14 Feb 2024.